Clinical trials: Follow-Up Study
Encephalitis, Tick-Borne
TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)
The purpose of this study is to assess: TBE antibody persistence 24, 34, 46 and 58 months (as applicable) after the first booster TBE vaccination with FSME-IMMUN 0.5ml given in Study 223, by means of ELISA (IMMUNOZYM FSME IgG)…
- Trial name
- NCT00503529
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 2 sites in Poland
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cognition Disorder, Nervous System Diseases
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
The purpose of this follow-up study is to assess the long-term safety and tolerability of galantamine in individuals with mild cognitive impairment who participated in a previous study with galantamine
- Conditions
- Cognition Disorder, Nervous System Diseases, Mental Disorders, Brain Diseases
- Trial name
- NCT00240695
- Testing
- galantamine hydrobromide
- Volunteers
- 724 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Kidney Transplantation
Study To Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation
The purpose of this study is to collect local laboratory data on immunoreactive parathyroid hormone (iPTH), calcium and phosphorus levels and estimated glomerular filtration rate (GFR) at approximately 1 week, 1 month, 3 months…
- Trial name
- NCT00110656
- Testing
- Observations
- Volunteers
- 38 people
- Sponsor
- Amgen
Shoulder Pain, Shoulder Injuries
MDR - Comprehensive Reverse/Versa Dial Ti Glenosphere
The objective of this retrospective/prospective consecutives series PMCF study is to collect data confirming safety, performance and clinical benefits of the Comprehensive Versa-Dial Reverse Ti Glenosphere when used for primary…
- Conditions
- Shoulder Pain, Shoulder Injuries, Shoulder Fractures, Shoulder Arthritis
- Trial name
- NCT04003272
- Testing
- Comprehensive Reverse Versa-Dial Titanium Glenosphere
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Zimmer Biomet
Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 9 years.
- Trial name
- NCT01517802
- Testing
- Abiraterone acetate, Prednisone
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Janssen Research & Development, LLC
Anemia, Kidney Diseases
DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)
This is a post-authorisation safety study to assess the incidence and severity of all pre-defined cardiovascular events in patients treated with DYNEPO, as well as to detect \& describe less common adverse drug reactions, and to…
- Conditions
- Anemia, Kidney Diseases, Renal Failure, Chronic, Kidney Failure, Chronic
- Trial name
- DELFT (NCT00664066)
- Testing
- DYNEPO (epoetin delta)
- Where
- 2 sites in Germany
- Volunteers
- 3 people
- Sponsor
- Shire
Heart Transplantation, Kidney Transplantation
A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients
The purpose of this study, a follow up to study FG506-CL-0403, is to see how safe and effective Modigraf® is (Part A) and to see how safe and effective it is to change your child's medication from Modigraf® to Prograf® (Part B).
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation
- Trial name
- PROGRESSION (NCT01371344)
- Testing
- Tacrolimus granules, Tacrolimus capsules
- Where
- 12 sites in Belgium, France and 4 more
- Volunteers
- 47 people
- Sponsor
- Astellas Pharma Europe Ltd.
Glaucoma, Open-Angle
A Study of the Rate of Progression of Glaucoma During a Follow-up Period of Two Years
This is an epidemiological, non-interventional, prospective study to collect data on glaucoma progression in a routine setting. Patients may receive treatment at the discretion of their physician per local standard of care.
- Trial name
- NCT01629407
- Testing
- Standard of Care
- Where
- Spain
- Volunteers
- 315 people
- Sponsor
- Allergan
Spinal Muscular Atrophy 1
Long-Term Follow-up Study for Patients From AVXS-101-CL-101
This is a long term, safety follow up study of patients in the AVXS-101-CL-101 gene replacement therapy clinical trial for SMA Type 1 delivering onasemnogene abeparvovec-xioi.
- Trial name
- START (NCT03421977)
- Testing
- Onasemnogene Abeparvovec-xioi
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Novartis Gene Therapies
Encephalitis, Tick-Borne
TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)
The purpose of this study is to assess the seropersistence of TBE antibodies in children and adolescents aged 1 to 15 years at the time of their first vaccination, 24 months and 34 months after completion of primary immunization…
- Trial name
- NCT00161967
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Pfizer
Epilepsy
Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy
N01372 study is to evaluate the long-term safety, tolerability, maintenance of efficacy of Brivaracetam (BRV); as well as the effect of BRV on subjects' health-related quality of life and to explore the direct medical resource…
- Trial name
- NCT01728077
- Testing
- Brivaracetam
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 26 people
- Sponsor
- UCB Pharma SA
Hepatitis C, Chronic
Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C
The purpose of this study is to determine whether lozenges of interferon-alpha that are dissolved in the mouth can prevent relapse in patients with hepatitis C virus infection who had a complete virologic response after receiving…
- Trial name
- NCT00695019
- Testing
- interferon-alpha lozenges
- Where
- 9 sites in Taiwan
- Volunteers
- 169 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Pre-Pectoral Breast Reconstruction Following Mastectomy
Retrospective Study of AlloMend Acellular Dermal Matrix (ADM) Allograft and Pre-Pectoral Breast Reconstruction
This retrospective, single-site study will provide information regarding the efficiency of AlloMend® Acellular Dermal Matrix allograft in Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.
- Trial name
- NCT06853964
- Testing
- AlloMend® Acellular Dermal Matrix allograft
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- AlloSource
Motion Sickness
Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI 386 Nasal Gel for the Prevention and Treatment of Nausea Associated with Motion Sickness in Senior Subjects With…
- Trial name
- NCT03988530
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Thoracic Aortic Aneurysm, Penetrating Aortic Ulcer
Zenith Thoracic Alpha (ZTA) Post-Market Data Collection
This study aims to gather real-world clinical data demonstrating the continued safety and performance of the a marketed stent graft (Zenith® Alpha Thoracic Endovascular Graft [ZTA]) and collect longer term follow-up to better…
- Trial name
- NCT06094127
- Testing
- Endovascular aortic treatment
- Where
- 10 sites in France, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Cook Research Incorporated
HIV
Long-term Follow-up of Study Participant Treated With Lentiviral-Based Genetically Modified Autologous Cell Product ,AGT103-T
Long-term follow-up of study subjects who received AGT103-T product in HIV study. The AGT103-T is genetically modified cells that resist infection with HIV causing a depletion of HIV in HIV-infected study participants.
- Trial name
- NCT05529342
- Testing
- Gene modified therapy
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- American Gene Technologies International Inc.
Joint Disease
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems
Sponsor is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) marketed in the European Union (EU) .
- Trial name
- NCT02239783
- Testing
- total hip arthroplasty implant
- Where
- Canada
- Volunteers
- 143 people
- Sponsor
- MicroPort Orthopedics Inc.
Partially Edentulous Jaw
Study on OsseoSpeed™ TX Implants in a Chinese Population
To investigate the clinical efficacy of OsseoSpeed™ TX implants in a Chinese population by evaluation of marginal bone level alteration, implant stability and implant survival in the posterior mandible up to 3 years after…
- Trial name
- NCT01346683
- Testing
- OsseoSpeed TX
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Dentsply Sirona Implants and Consumables
Symptomatic Vitreomacular Adhesion
Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies
The primary objective of this study is to assess visual function in up to 44 patients who have previously participated in either of the placebo controlled, ocriplasmin Phase III studies (TG-MV-006 or TG-MV-007).
- Trial name
- NCT01287988
- Testing
- ocriplasmin
- Where
- 2 sites in United States, Belgium
- Volunteers
- 24 people
- Sponsor
- ThromboGenics
B-cell Mediated Autoimmune Disorders
Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel
The main objective of this study is to collect data on the long-term safety of azer-cel, primarily through the capture of clinical events of interest (CEI) for up to 15 years following participation in TG-Azercel -101 study.
- Trial name
- NCT07577583
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- TG Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.